PTHS

Pelthos Therapeutics Inc. (PTHS) SWOT Analysis Analysis (2026)

Invetso Score: 2.3/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.4 (Weak)

Liquidity ratios above 1.0 indicate near-term obligations are covered, but peers with stronger cash generation typically sustain more resilient working-capital profiles.

A current ratio of 1.98 and quick ratio of 1.31 provide some balance-sheet flexibility, yet they do not offset the company’s weaker operating efficiency versus peers.

The absence of disclosed margin data limits evidence of operating leverage, leaving the company structurally less transparent than peers with clearer profitability profiles.

Weaknesses

Score:

Return on invested capital of -49.4% signals severe capital destruction, placing the company well below peers that at least preserve invested capital over time.

Cash conversion cycle of 412.8 days indicates capital is tied up far longer than peers, which depresses liquidity and constrains reinvestment capacity.

Negative net debt to EBITDA and debt-to-equity readings suggest the metric set is distorted by weak earnings and equity structure, underscoring a fragile financial profile versus peers.

Opportunities

Score:

Working-capital normalization could materially improve cash generation because the current 412.8-day cash conversion cycle leaves more room for peers to outperform on efficiency.

If operating discipline improves, the company could narrow the gap with peers by converting its current liquidity buffer into more productive reinvestment.

The lack of segment concentration data leaves open the possibility of portfolio simplification, which could strengthen positioning relative to more complex peers.

Threats

Score:

Peers with positive returns on capital can compound faster, making the company’s negative ROIC a structural disadvantage in attracting capital and sustaining valuation.

An extended cash conversion cycle increases dependence on external funding, leaving the company more exposed than peers if credit conditions tighten.

Without visible margin strength, the company remains vulnerable to peers that can absorb pricing pressure and protect profitability more effectively.

Overall Score

Score:

PTHS appears structurally weak versus peers because negative capital returns and extreme working-capital intensity outweigh its limited liquidity cushion.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Pelthos Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →